Patients’ View Of Drug Value Is Focus Of Avalere/FasterCures Framework
Executive Summary
Cost considerations will be limited to those borne by patients under value framework that is expected to be used initially to support patient-clinician decisions on appropriate treatment.
You may also be interested in...
Valuing Drugs In The US: How We're Doing And What's Ahead
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.
As Drug Value Frameworks Gain Traction, Patients Seek More Input
'Patients are ready and willing to have conversations' about trade-offs, National Health Council's Perfetto says.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.